Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease.

ABSTRACT: In the last decade, treatment for castration-resistant prostate cancer has changed markedly, impacting symptom control and longevity for patients. However, a large proportion of cases progress despite androgen deprivation therapy and chemotherapy, while still being fit enough for several more lines of treatment. Overstimulation of the androgen receptor (AR) activity is the main driver of this cancer. Targeting biological functions of the AR or its co-regulators has proven very effective in this disease and led to the development of several highly effective drugs targeting the AR signalling axis. Drugs such as enzalutamide demonstrated that the improvement in anti-tumour efficacy is closely correlated with an affinity for the AR and its activity and have established the paradigm that AR rem

SUBMITTER: Maylin ZR 

PROVIDER: S-EPMC8138777 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature